UK - The £400m Roche Products Pension Fund has lambasted consultants Hewitt Bacon & Woodrow (HB&W) and has decided to sever a 24 year relationship with the firm.
Secretary to the fund for the pharmaceuticals company Douglas Ross said that the decision to replace Hewitt Bacon & Woodrow - which formed part of a “good practice” review - was driven by dissatisfaction over “poor service” and HB&W’s “complacent attitude”.
Other allegations levelled at HB&W include high charges and “missing deadlines”.
Roche has now chosen rivals Watson Wyatt to provide actuarial, administration, investment and communications services for the scheme which has 5,000 members. The firm will conduct an actuarial review for Roche next April.
A spokesman for Hewitt Bacon & Woodrow said: We believe that every effort was made to fulfil Roche's requirements and we regret the loss of their business just as we would regret the loss of any other client.
Hewitt Bacon & Woodrow has made some significant new business gains in recent weeks - including being appointed by Roche UK's Swiss parent company to advise on global benefit strategy. We will continue in our bid to provide both them and all our clients with the highest possible standards of service and expertise.
By Madhu Kalia
Guy Opperman has rejected calls to speed up changes to auto-enrolment (AE) despite increasing pressure to boost contribution rates and overall savings pots.
Pensions and Benefits UK 2019 is delighted to announce the launch of our programme for this year, celebrating 20 years of bringing you the latest updates on all things pensions and employee benefits. Register for your place today!
PP has compiled a list of what to watch out for over the coming months.
Willis Towers Watson's LifeSight is the first master trust to be granted authorisation by The Pensions Regulator (TPR).